Madrigal Pharma (MDGL): FDA Approves rezdiffra
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Join SI Premium – FREE
(Updated - March 14, 2024 3:52 PM EDT)
Madrigal Pharma (NASDAQ: MDGL): FDA Approves rezdiffra - website.
- Rezdiffra indicated in conjunction with diet, exercise for treatment of adults with NASH with moderate to advanced liver fibrosis.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA grants fast track status to Aclaris drug for lichen planus
- Theriva Biologics doses first patient in VIRAGE2 pancreatic cancer trial
- Pacira publishes two-year Phase 1 data for knee OA gene therapy
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA NewsRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
